P-tau217 demonstrated a higher fold change than p-tau181 in distinguishing AD from clinical FTLD-spectrum disorders (3.5-fold vs. 2.4-fold), FTLD-tau (4.1-fold vs. 2.8-fold), and FTLD-TDP (5.6-fold vs. 3.7-fold) [102]. This evidence concerns the gene MAPT and Alzheimer disease.